MA54823A - Composé hétérocyclique et son utilisation - Google Patents

Composé hétérocyclique et son utilisation

Info

Publication number
MA54823A
MA54823A MA054823A MA54823A MA54823A MA 54823 A MA54823 A MA 54823A MA 054823 A MA054823 A MA 054823A MA 54823 A MA54823 A MA 54823A MA 54823 A MA54823 A MA 54823A
Authority
MA
Morocco
Prior art keywords
heterocyclic compound
heterocyclic
compound
Prior art date
Application number
MA054823A
Other languages
English (en)
Inventor
Masaki Daini
Shuhei Ikeda
Makoto Kamata
Takahito Kasahara
Fumiaki Kikuchi
Osamu Kubo
Satoshi Mikami
Shinji Morimoto
Masataka Murakami
Minoru Nakamura
Yuya Oguro
Florian Puenner
Sachie Takashima
Akinori Toita
Fumie Yamaguchi
Takafumi Yukawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA54823A publication Critical patent/MA54823A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA054823A 2019-01-24 2020-01-23 Composé hétérocyclique et son utilisation MA54823A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019010536 2019-01-24

Publications (1)

Publication Number Publication Date
MA54823A true MA54823A (fr) 2022-04-27

Family

ID=71736449

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054823A MA54823A (fr) 2019-01-24 2020-01-23 Composé hétérocyclique et son utilisation

Country Status (5)

Country Link
US (1) US12637418B2 (fr)
EP (1) EP3915638A4 (fr)
JP (1) JP7541487B2 (fr)
MA (1) MA54823A (fr)
WO (1) WO2020153414A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774800B1 (fr) * 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
CN115354349B (zh) * 2022-08-29 2025-07-18 河北农业大学 一种电催化制备过氧化氢的碳催化剂的制备方法及催化剂
CN116120226A (zh) * 2022-12-28 2023-05-16 湖南阿斯迪康药业有限公司 一种5-羟甲基烟腈的合成工艺

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
TW212792B (fr) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
US5252563A (en) 1991-12-19 1993-10-12 G. D. Searle & Company 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
CA2191979A1 (fr) 1994-06-20 1995-12-28 Muneo Takatani Composes d'imidazole condenses, leur production et utilisation
JP3439551B2 (ja) 1994-11-08 2003-08-25 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
CA2214247C (fr) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
KR20000022398A (ko) 1996-07-05 2000-04-25 모치다 에이 신규 벤조이미다졸 유도체
EP1586584A1 (fr) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulateurs de l'agrégation de peptides beta-amyloides, comprenant des D-aminoacides
US6420415B1 (en) 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
JP2000159747A (ja) 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1194449B1 (fr) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibiteurs de memapsine 2 et son utilisation
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US20020151534A1 (en) 2001-02-02 2002-10-17 Ries Uwe Joerg Antithrombotic compounds
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
EP1375472A4 (fr) 2001-03-30 2008-12-10 Eisai R&D Man Co Ltd Compose de benzene et sel de ce compose
WO2002080899A1 (fr) 2001-03-30 2002-10-17 Eisai Co., Ltd. Agent de traitement de maladie digestive
EP1390034A4 (fr) 2001-04-03 2005-07-13 Merck & Co Inc Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
JP2004002405A (ja) 2002-04-26 2004-01-08 Takeda Chem Ind Ltd 新規チオール誘導体、その製造法および用途
CA2483515A1 (fr) 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Nouveau derive de thiol, procede de production de ce derive et utilisation dudit derive
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Jnk阻害剤
WO2004054977A1 (fr) 2002-12-13 2004-07-01 Cytopia Pty Ltd Inhibiteurs de kinase a base de nicotinamide
CA2521907A1 (fr) 2003-04-10 2004-10-21 Pfizer Inc. Composes bicycliques comme antagonistes du recepteur nr2b
US20050137187A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
AR057218A1 (es) 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法
WO2007098352A2 (fr) 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Pyridineamides substitués pouvant être employés en tant qu'inhibiteurs d'époxyde hydrolase soluble
JP2010120852A (ja) 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
WO2009004430A1 (fr) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate
AU2010210426B2 (en) 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
BR112012021806A2 (pt) 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
EP2694509B1 (fr) 2011-04-05 2016-05-18 Pfizer Limited Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine
WO2012158691A1 (fr) 2011-05-19 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Composés antiprolifératifs et procédés pour leur utilisation
EP2721029B1 (fr) 2011-06-16 2018-07-18 Merck Sharp & Dohme Corp. Dérivés d'imidazopyridin-2-one
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
CA3188023C (fr) 2013-03-08 2025-03-11 Becton, Dickinson And Company Dispositif de verrouillage d'accès de seringue intraveineuse
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
CA2939639C (fr) 2014-02-24 2023-01-24 Takeda Gmbh Proteines de fusion d'uti
CN107074788B (zh) 2014-10-31 2019-09-20 厦门大学 取代杂环衍生物、其制备方法和用途
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
TWI636041B (zh) 2015-08-12 2018-09-21 美國禮來大藥廠 Cgrp受體拮抗劑
WO2017033946A1 (fr) 2015-08-25 2017-03-02 武田薬品工業株式会社 Composé hétérocyclique
PL3439477T3 (pl) 2016-04-08 2020-11-16 Syngenta Participations Ag Mikrobiocydowe pochodne oksadiazolowe
EP3636281B1 (fr) 2017-05-09 2023-11-01 Zhejiang University Méthode de traitement de la dépression, et composition pharmaceutique
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3774800B1 (fr) 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
WO2020154314A1 (fr) 2019-01-21 2020-07-30 Transit Scientific, LLC Cathéters à hypotube
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
WO2020196828A1 (fr) 2019-03-28 2020-10-01 武田薬品工業株式会社 Composé hétérocyclique contenant de l'azote
WO2020198710A1 (fr) 2019-03-28 2020-10-01 Essa Pharma, Inc. Compositions et associations pharmaceutiques comprenant des inhibiteurs du récepteur des androgènes et leurs utilisations
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Also Published As

Publication number Publication date
US12637418B2 (en) 2026-05-26
US20220089525A1 (en) 2022-03-24
EP3915638A1 (fr) 2021-12-01
JPWO2020153414A1 (ja) 2021-12-02
WO2020153414A1 (fr) 2020-07-30
EP3915638A4 (fr) 2022-10-19
JP7541487B2 (ja) 2024-08-28

Similar Documents

Publication Publication Date Title
EP3816153A4 (fr) Composé hétérocyclique et son utilisation
EP3816154A4 (fr) Composé hétérocyclique et son application
EP4071145A4 (fr) Composé inhibiteur de jak et son utilisation
EP3932919A4 (fr) Composé inhibiteur de jak et son utilisation
EP3663281A4 (fr) Composé hétérocyclique et son application
EP3929199A4 (fr) Nouveau composé hétérocyclique et utilisation associée
EP3896060A4 (fr) Composé hétérocyclique
EP3798219A4 (fr) Composé de dihydronaphtyridine substitué par phényle et son utilisation
EP3895707A4 (fr) Composé hétérocyclique
MA43963A (fr) Composé de pipéridine substituée et son utilisation
EP3919055A4 (fr) Composé hétérocyclique
EP4066893A4 (fr) Composé hétérocyclique
EP3792248A4 (fr) Composé benzamide et son application
EP3950674A4 (fr) Composé pyrrole amide et son utilisation
EP3981769A4 (fr) Composé de pyrrolopyrimidine et son utilisation
EP3674352A4 (fr) Composé dérivé de lignine et son utilisation
MA52214A (fr) Composé hétérocyclique et son utilisation
EP3890738A4 (fr) Composé macrocyclique et son utilisation
EP3888652A4 (fr) Composé hétérocyclique
EP3681877A4 (fr) Composé dérivé de pyrazole et son utilisation
EP4039686A4 (fr) Composé bicyclique et son utilisation
EP3978468A4 (fr) Composé et composition
MA52297A (fr) Composé hétérocyclique
EP4082614A4 (fr) Composé acylsulfamide et son utilisation pharmaceutique
EP4361138A4 (fr) Composé sulfoximine et son utilisation